Galecto (GLTO)
(Delayed Data from NSDQ)
$12.93 USD
-1.22 (-8.62%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $12.90 -0.03 (-0.23%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Galecto, Inc. [GLTO]
Reports for Purchase
Showing records 1 - 7 ( 7 total )
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Data Suggest GB1211 Lung Cancer Potential; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Reprioritization and Restructuring Initiated; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
GALACTIC-1 Study Failure; Reiterate Buy; Lowering PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
Key Milestones Approaching; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
GALACTIC-1 Study Dosing Concluded; Top-Line Data in August; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
Disrupting Fibrosis and Cancer Treatment; Initiating at Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
|